Probiotics in Mild Alzheimer's Disease
Recruiting · NCT06181513 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Nicosia
View the official record on ClinicalTrials.gov →Interventions studied
Probiotic Blend Capsule
What this trial is about
The main objective is to investigate whether administration of probiotics to patients with mild Alzheimer's Disease (AD) reduces neuroinflammation, improves cognitive function and modifies neurophysiological measures, compared to a patient group that receives placebo (no active probiotics).
Who can take part
Age range
65 Years to 85 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Early Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Adults ≥65 years, able to give consent
- Mini-Mental State Examination (MMSE) scores 19-23 (mild AD)
- approximately equal male:female ratio
Exclusion criteria
- Inability to give consent
- other neurological disease
- relevant psychiatric disorders (e.g. major depression)
- gastrointestinal/metabolic conditions
- history of alcohol/substance dependence
- use of systemic antibiotics in the previous 6 months
- corticosteroid use
- immune stimulating medications
- immunosuppressive agents
- probiotics consumption in the previous 6 months.
- immunosuppression
- structural heart disease
- neutropenia
- radiation
- active intestinal disease
Where it is running
1 location listed.
- The Cyprus Institute of Neurology and Genetics - Nicosia, Cyprus